BROOKLINE CAPITAL ACQUISITIO (BCAC)
US11374E1047 - Common Stock
BROOKLINE CAPITAL ACQUISITIO
NASDAQ:BCAC (7/29/2022, 7:00:01 PM)
After market: 16.11 -6.6 (-29.06%)22.71
+12.63 (+125.3%)
Company Profile
Brookline Capital Acquisition Corp. is a blank check company which intends to focus its search on companies in the life sciences industry. The company is headquartered in New York City, New York. The company went IPO on 2021-02-02. The firm is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The firm may pursue an acquisition opportunity in any industry or sector, it intends to source, acquire and manage a business in the life sciences industry. The firm has not conducted any operations and has not generated any revenues.
Company Info
BROOKLINE CAPITAL ACQUISITIO
280 Park Avenue, Suite 43W
New York City NEW YORK 10022
P: 16466036716.0
CEO: Samuel P. Wertheimer
Employees: 0
BCAC News
2 years ago - Moore Kuehn, PLLCMoore Kuehn Encourages VCKA, RNER, BCAC, and SUMR Investors to Contact Law Firm/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
5 years ago - Bison Capital Acquisition Corp.Bison Capital Acquisition Corp. Announces the Postponement of the Meeting Date for the Special Meeting of Shareholders to Approve Business Combination with Xynomic Pharmaceuticals, Inc.5 years ago - Bison Capital Acquisition Corp.Bison Capital Acquisition Corp. Announces Record and Meeting Dates for the Special Meeting of Shareholders to Approve Business Combination with Xynomic Pharmaceuticals, Inc.
5 years ago - Xynomic Pharmaceuticals, Inc.Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer5 years ago - Xynomic Pharmaceuticals, Inc.Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials
5 years ago - TalkMarketsWeek In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific ImmunotherapiesNJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts.
BCAC Twits
Here you can normally see the latest stock twits on BCAC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
